One of the binding proteins for administered amyloid-β appears to be anti-Aβ IgG antibody in amyloid plaques.

Reisuke H Takahashi, Mayumi Yokotsuka, Ayako Nakamura, Toshitaka Nagao, Gunnar K Gouras, Toshiki Uchihara

Abstract read

In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Reisuke H TakahashiDepartment of Anatomic Pathology, Tokyo Medical University, Shinjuku, Tokyo, Japan.

Mayumi YokotsukaDepartment of Anatomic Pathology, Tokyo Medical University, Shinjuku, Tokyo, Japan.

Ayako NakamuraLaboratory of Structural Neuropathology, Tokyo Metropolitan Institute of Medical Science, Setagaya, Tokyo, Japan.

Toshitaka NagaoDepartment of Anatomic Pathology, Tokyo Medical University, Shinjuku, Tokyo, Japan.ORCID 0000-0003-2075-9738

Gunnar K GourasExperimental Dementia Research Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden.

Toshiki UchiharaInternal Medicine, Okinawa Chubu Hospital, Uruma, Okinawa, Japan.ORCID 0000-0002-5881-5419

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundAmyloid-β peptides (Aβ) applied to Alzheimer's disease (AD) brain bind to amyloid plaques (APs) and this binding is saturable. Meanwhile, anti-immunoglobulin G (IgG) antibodies label APs. Considering the saturable binding of Aβ to APs and the localization of IgGs in APs, specific binding proteins (BPs) for the applied Aβ could be anti-Aβ IgG antibodies (anti-AβAbs) in APs.ObjectiveOur objective is to demonstrate whether anti-AβAbs are the BPs for administered Aβ in APs.MethodsTo identify the binding specificity, we established a tissue competition assay utilizing the competitiveness of ligand specificity to BPs. Biotinylated Aβ

Indexed as

Amyloid beta-PeptidesImmunoglobulin GPeptide FragmentsPlaque, AmyloidAlzheimer DiseaseAnimalsBrainHumansMaleProtein BindingAmyloid beta-Peptidesamyloid beta-protein (1-42)Immunoglobulin GPeptide FragmentsAlzheimer's diseaseamyloid plaquesamyloid-β peptideanti-Aβ IgG antibodycompetition assayultrahigh-resolution imaging

Identifiers

PMID41166188

DOI10.1177/13872877251389631

PMCPMC13022022

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.